Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

A Pan-Cancer Analysis of the Oncogenic Role of YES Proto-Oncogene 1 (YES1) in Human Tumors.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: A Pan-Cancer Analysis of the Oncogenic Role of YES Proto-Oncogene 1 (YES1) in Human Tumors.
Συγγραφείς: Dou R; Department of Anesthesiology, Huadong Hospital, Fudan University, Shanghai, China., Han L; Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, China., Liu G; Department of Emergency Surgery, Huadong Hospital, Fudan University, Shanghai, China.; Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China., Zhu X; Department of General Practice, Community Health Service Center of Xinjing Town, Shanghai, China., Yang Z; Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China., Hu P; Department of Emergency Surgery, Huadong Hospital, Fudan University, Shanghai, China.; Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China., Su Y; Department of Emergency Surgery, Huadong Hospital, Fudan University, Shanghai, China.; Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China.
Πηγή: The journal of gene medicine [J Gene Med] 2025 Nov; Vol. 27 (11), pp. e70046.
Τύπος έκδοσης: Journal Article; Research Support, Non-U.S. Gov't
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: John Wiley & Sons Country of Publication: England NLM ID: 9815764 Publication Model: Print Cited Medium: Internet ISSN: 1521-2254 (Electronic) Linking ISSN: 1099498X NLM ISO Abbreviation: J Gene Med Subsets: MEDLINE
Imprint Name(s): Original Publication: Chichester, UK : John Wiley & Sons
Ιατρικοί όροι (MeSH): Neoplasms*/genetics , Neoplasms*/metabolism , Neoplasms*/pathology , Proto-Oncogene Proteins c-yes*/genetics , Proto-Oncogene Proteins c-yes*/metabolism, Computational Biology/methods ; Tumor Microenvironment/genetics ; Biomarkers, Tumor/genetics ; Humans ; Proto-Oncogene Mas ; Gene Expression Regulation, Neoplastic ; Signal Transduction ; Prognosis ; Gene Expression Profiling
Περίληψη: Background: Numerous studies have underscored the oncogenic function of YES Proto-Oncogene 1 (YES1) in various tumors. However, the relationship between YES1 and different tumors in pan-cancer patients, based on extensive clinical data, remains unclear.
Methods: Integrating data from bioinformatics platforms (TIMER2, GEPIA2, UALCAN, cBioPortal, UniProt, STRING, and DAVID), we systematically interrogated YES1 expression patterns across malignancies. Multidimensional assessments encompassing clinical outcomes, genetic alteration profiles, post-translational modifications, and immunocyte infiltration dynamics were performed. Pathway enrichment mapping was subsequently applied to delineate oncogenic signaling networks.
Results: Tumor-type-specific YES1 expression signatures demonstrated significant prognostic stratification capacity. Molecular profiling revealed some core pathological mechanisms: genomic instability hotspots, phosphoproteomic deregulation in malignancies, and CAF-dominated tumor microenvironment remodeling in mesenchymal neoplasms. Systems biology approaches further uncovered YES1-mediated coordination of hallmark cancer processes, particularly cancer-related signaling pathways and protein processing functions.
Conclusion: This initial systematic pan-cancer investigation establishes YES1 as a pleiotropic oncogenic regulator, with mechanistic heterogeneity across tumor lineages. The multidimensional characterization provides a translational framework for developing lineage-specific therapeutic strategies targeting YES1 signaling networks.
(© 2025 John Wiley & Sons Ltd.)
References: R. Myerson, T. Lu, Y. Yuan, and G. G. Liu, “Cancer Diagnosis and Care Among Rural‐to‐Urban Migrants in China,” BMJ Global Health 4 (2019): e001923, https://doi.org/10.1136/bmjgh‐2019‐001923.
L. Hui and Y. Chen, “Tumor Microenvironment: Sanctuary of the Devil,” Cancer Letters 368 (2015): 7–13, https://doi.org/10.1016/j.canlet.2015.07.039.
A. Blum, P. Wang, and J. C. Zenklusen, “SnapShot: TCGA‐Analyzed Tumors,” Cell 173 (2018): 530, https://doi.org/10.1016/j.cell.2018.03.059.
K. Tomczak, P. Czerwińska, and M. Wiznerowicz, “The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge,” Contemporary Oncology 19 (2015): A68–A77, https://doi.org/10.5114/wo.2014.47136.
E. Clough and T. Barrett, “The Gene Expression Omnibus Database,” in Methods in Molecular Biology, vol. 1418 (Humana Press, 2016), 93–110, https://doi.org/10.1007/978‐1‐4939‐3578‐9_5.
J. Schlessinger, “New Roles for Src Kinases in Control of Cell Survival and Angiogenesis,” Cell 100 (2000): 293–296, https://doi.org/10.1016/s0092‐8674(00)80664‐9.
Y. Touil, W. Igoudjil, M. Corvaisier, et al., “Colon Cancer Cells Escape 5FU Chemotherapy‐Induced Cell Death by Entering Stemness and Quiescence Associated With the c‐Yes/YAP Axis,” Clinical Cancer Research 20 (2014): 837–846, https://doi.org/10.1158/1078‐0432.Ccr‐13‐1854.
I. Garmendia, M. J. Pajares, F. Hermida‐Prado, et al., “YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib,” American Journal of Respiratory and Critical Care Medicine 200 (2019): 888–899, https://doi.org/10.1164/rccm.201807‐1292OC.
N. Hamanaka, Y. Nakanishi, T. Mizuno, et al., “YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification,” Cancer Research 79 (2019): 5734–5745, https://doi.org/10.1158/0008‐5472.Can‐18‐3376.
P. D. Fan, G. Narzisi, A. D. Jayaprakash, et al., “YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics,” Proceedings of the National Academy of Sciences of the United States of America 115 (2018): E6030–E6038, https://doi.org/10.1073/pnas.1717782115.
S. J. Parsons and J. T. Parsons, “Src Family Kinases, Key Regulators of Signal Transduction,” Oncogene 23 (2004): 7906–7909, https://doi.org/10.1038/sj.onc.1208160.
B. Sen and F. M. Johnson, “Regulation of SRC Family Kinases in Human Cancers,” Journal of Signal Transduction 2011 (2011): 865819, https://doi.org/10.1155/2011/865819.
M. Lapouge and S. Meloche, “A Renaissance for YES in Cancer,” Oncogene 42 (2023): 3385–3393, https://doi.org/10.1038/s41388‐023‐02860‐x.
E. Kook, J. Lee, and D. H. Kim, “YES1 as a Potential Target to Overcome Drug Resistance in EGFR‐Deregulated Non‐Small Cell Lung Cancer,” Archives of Toxicology 98 (2024): 1437–1455, https://doi.org/10.1007/s00204‐024‐03693‐7.
H. Zhou, D. Sun, J. Tao, M. Xu, X. Zhang, and H. Hou, “Role of YES1 Signaling in Tumor Therapy Resistance,” Cancer Innovation 2 (2023): 210–218, https://doi.org/10.1002/cai2.51.
E. Redin, E. M. Garrido‐Martin, K. Valencia, et al., “YES1 Is a Druggable Oncogenic Target in SCLC,” Journal of Thoracic Oncology 17 (2022): 1387–1403, https://doi.org/10.1016/j.jtho.2022.08.002.
L. Mao, W. Yuan, K. Cai, et al., “EphA2‐YES1‐ANXA2 Pathway Promotes Gastric Cancer Progression and Metastasis,” Oncogene 40 (2021): 3610–3623, https://doi.org/10.1038/s41388‐021‐01786‐6.
W. C. Hahn and R. A. Weinberg, “Rules for Making Human Tumor Cells,” New England Journal of Medicine 347 (2002): 1593–1603, https://doi.org/10.1056/NEJMra021902.
D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell 100 (2000): 57–70, https://doi.org/10.1016/s0092‐8674(00)81683‐9.
T. Hunter, “Signaling—2000 and Beyond,” Cell 100 (2000): 113–127, https://doi.org/10.1016/s0092‐8674(00)81688‐8.
M. E. Huot, G. Vogel, A. Zabarauskas, et al., “The Sam68 STAR RNA‐Binding Protein Regulates mTOR Alternative Splicing During Adipogenesis,” Molecular Cell 46 (2012): 187–199, https://doi.org/10.1016/j.molcel.2012.02.007.
R. Fan, F. Liu, Q. Gong, D. Liu, S. Tang, and D. Shen, “KHDRBS1 as a Novel Prognostic Signaling Biomarker Influencing Hepatocellular Carcinoma Cell Proliferation, Migration, Immune Microenvironment, and Drug Sensitivity,” Frontiers in Immunology 15 (2024): 1393801, https://doi.org/10.3389/fimmu.2024.1393801.
X. Liu, X. Liu, W. Dong, et al., “KHDRBS1 Regulates the Pentose Phosphate Pathway and Malignancy of GBM Through SNORD51‐Mediated Polyadenylation of ZBED6 Pre‐mRNA,” Cell Death & Disease 15 (2024): 802, https://doi.org/10.1038/s41419‐024‐07163‐x.
H. Y. Liao, C. M. Da, B. Liao, and H. H. Zhang, “Roles of Matrix Metalloproteinase‐7 (MMP‐7) in Cancer,” Clinical Biochemistry 92 (2021): 9–18, https://doi.org/10.1016/j.clinbiochem.2021.03.003.
G. Bindea, B. Mlecnik, M. Tosolini, et al., “Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer,” Immunity 39 (2013): 782–795, https://doi.org/10.1016/j.immuni.2013.10.003.
A. El‐Kenawi, K. Hänggi, and B. Ruffell, “The Immune Microenvironment and Cancer Metastasis,” Cold Spring Harbor Perspectives in Medicine 10 (2020): a037424, https://doi.org/10.1101/cshperspect.a037424.
M. Tsoumakidou, “The Advent of Immune Stimulating CAFs in Cancer,” Nature Reviews. Cancer 23 (2023): 258–269, https://doi.org/10.1038/s41568‐023‐00549‐7.
E. Sahai, I. Astsaturov, E. Cukierman, et al., “A Framework for Advancing Our Understanding of Cancer‐Associated Fibroblasts,” Nature Reviews. Cancer 20 (2020): 174–186, https://doi.org/10.1038/s41568‐019‐0238‐1.
H. Zhang, X. Yue, Z. Chen, et al., “Define Cancer‐Associated Fibroblasts (CAFs) in the Tumor Microenvironment: New Opportunities in Cancer Immunotherapy and Advances in Clinical Trials,” Molecular Cancer 22 (2023): 159, https://doi.org/10.1186/s12943‐023‐01860‐5.
Grant Information: 82002537 Natural Science Foundation of China
Contributed Indexing: Keywords: YES1; cancer‐associated fibroblast; phosphorylation; prognosis; tumor
Substance Nomenclature: 0 (Proto-Oncogene Mas)
0 (MAS1 protein, human)
EC 2.7.10.2 (Proto-Oncogene Proteins c-yes)
EC 2.7.10.2 (YES1 protein, human)
0 (Biomarkers, Tumor)
Entry Date(s): Date Created: 20251125 Date Completed: 20251125 Latest Revision: 20260319
Update Code: 20260320
DOI: 10.1002/jgm.70046
PMID: 41287103
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1521-2254
DOI:10.1002/jgm.70046